CAR T therapy

February 28, 2019

VICC launches new telehealth program for CAR-T patients

Some cancer patients receiving CAR-T infusions can now avoid hospital stays because of a telemedicine program launched by Vanderbilt-Ingram Cancer Center.

By Tom Wilemon
November 1, 2018

Team’s findings show glutamine metabolism affects T cell signaling

The cellular nutrient glutamine launches a metabolic signaling pathway that promotes the function of some immune system T cells and suppresses others, Vanderbilt researchers have discovered.

By Leigh MacMillan
October 25, 2017

Vanderbilt-Ingram Cancer Center patients treated with new FDA-approved CAR T therapy

Vanderbilt-Ingram Cancer Center (VICC) has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR T) therapy for treatment of adult patients with a specific type of lymphoma. VICC is the only cancer center in a seven-state region of the Southeast authorized to deliver the new immunotherapy.

By VUMC News and Communications